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InfectionTwo new tricyclic polyketides, vanitaracin A (1) and B (2), together with three novel compounds 3, 4 and
5, were isolated from a culture broth of a fungus, Talaromyces sp. The chemical structures of these
compounds were determined from spectroscopic data (1D/2D NMR, MS and IR). The ﬁve isolated com-
pounds were then tested for anti-hepatitis B virus (HBV) activity and vanitaracin A was found to exhibit
an IC50 value of 10.5 lM using a HBV-susceptible cell line. By contrast, the derivative 2 displayed weak
anti-HBV action, which suggested that the substituents at C-9 in 1 are likely to be important for its
antiviral activity. We believe the two vanitaracin derivatives constitute a new class of anti-HBV agents.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Chronic infection of hepatitis B virus (HBV) is a common cause
of liver diseases such as liver cirrhosis and hepatocellular carci-
noma.1 It is estimated that over 240 million people worldwide
are chronically infected with HBV, of whom 780,000 people will
eventually die of either liver disease or hepatocellular carcinoma
each year.2 Current therapies to combat chronic HBV infection
include interferon treatment (interferon-a and pegylated-
interferon-a), which primarily modulates immune response, and
nucleos(t)ide analogs (Lamivudine, Adefovir, Entecavir,
Telbivudine and Tenofovir), which inhibit the reverse transcriptase
of HBV.3,4 Although these drugs can deliver signiﬁcant clinical
improvement, there are serious problems associated with this
treatment including the emergence of drug-resistant viruses and
severe side effects.5,6 Consequently, there is an urgent need to
develop a novel class of anti-HBV agents with a different molecular
target.
Bioactive products obtained from fungal metabolites have
yielded some of the most important natural products for the phar-
maceutical industry.7 In the past, we have focused on fungi isolated
from sand, seaweed, mosses and plants to obtain natural products
to construct a library of compounds. Subsequent screening of our
library has resulted in the discovery of several valuable bioactive
compounds, including anti-hepatitis C virus agents.8–11 Here, wedescribe the isolation, structural elucidation and anti-HBV activity
of two new tricyclic polyketides; vanitaracin A (1) and B (2).
During the course of this investigation we also identiﬁed three
novel compounds 3–5.
Repeated separation of a culture extract from a fungus,
Talaromyces sp.,12 using silica gel chromatography yielded com-
pounds 15 (Fig. 1).13 The molecular formula of C25H34O7 for com-
pound 114 was determined by HRESIMS. The IR spectrum showed
the presence of a hydroxy group (3409 cm1) and carbonyl groups
(1735 cm1 and 1693 cm1). The 13C NMR spectrum revealed all
twenty-ﬁve carbon atoms, comprising; three carbonyl carbons,
seven quaternary carbons, ﬁve methine carbons, four methylene
carbons and six methyl carbons (Table 1). 1H NMR signals at d
10.51 (1H, br s), d 6.27 (1H, s) and d 4.61 (1H, s) and HMQC spec-
trum indicated the presence of three hydroxy groups. The 13C NMR
spectrum and HMBC correlations of H-7 (d 7.12) with C-5 (d 128.9),
C-6 (d 160.3), C-8 (d 146.4) and C-13 (d 119.1) showed the presence
of a tetrasubstituted phenol (Fig. 2). The phenol ring was found to
be connected to a partial structure of –CH2–CH(OH)–CH2–
CH(CH3)– established on the basis of 1H–1H COSY correlations from
H-1 to H-4 and HMBC correlations from H3-15 to C-3, C-4 and C-5.
Furthermore, HMBC correlations from H3-17 to two ketone car-
bons, C-10 (d 204.5) and C-12 (d 191.3), and C-11, and correlations
from H3-16 to C-8, C-9 and C-10 revealed the tricyclic core struc-
ture of 1 as shown in Figure 1. 1H–1H COSY correlations, and
HMBC correlations from H3-70 to C-10 (d 174.4), C-20 and C-30
revealed that 1 possessed a 2,4-dimethylhexanoate unit. All
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Figure 2. Key HMBC, 1H–1H COSY and NOESY correlations of compound 1.
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Figure 1. Structures of compounds 1–5.
4326 H. Matsunaga et al. / Bioorg. Med. Chem. Lett. 25 (2015) 4325–4328hydroxy proton signals could be assigned to 2-OH, 6-OH and 9-OH
on the basis of HMBC correlations of these protons, which
suggested that the 2,4-dimethylhexanoic acid unit was attached
to the core structure of 1 at C-11. The syn relationship of
OH-2/H3-15 was deduced from the NOESY correlation between
H-2 and H-4 (Fig. 2). Thus the structure of compound 1 was
determined as shown in Figure 1, and named vanitaracin A.
Efforts to determine the conﬁgurations at C-9, C-11, C-20 and C-40
are currently underway.
The molecular formula of C24H32O6 for compound 215 was
determined by HRESIMS. The 1H NMR spectrum suggested that
the structure of compound 2 was similar to compound 1, exceptTable 1
1H (600 MHz) and 13C (150 MHz) NMR spectroscopic data for compounds 1 and 2
Position 1a
dC, type dH (J in Hz)
1 36.6, CH2 3.46, m
2.57, m
2 64.6, CH 3.88, m
2-OH 4.61, s
3 37.7, CH2 1.99, m
1.51, ddd (13.1, 6.8,
4 27.4, CH 3.10, ddq (6.8, 6.8, 6
5 128.9, C
6 160.3, C
6-OH 10.51, brs
7 110.3, CH 7.12, s
8 146.4, C
9 74.5, C
9-OH 6.27, s
10 204.5, C
11 84.1, C
12 191.3, C
13 119.1, C
14 138.9, C
15 22.2, CH3 1.31, d (6.8)
16 32.4, CH3 1.47, s
17 22.9, CH3 1.42, s
10 174.4, C
20 36.2, CH 2.61, m
30 40.5, CH2 1.62, ddd (13.5, 9.4,
1.10, m
40 31.5, CH 1.44, m
50 29.2, CH2 1.27, m
1.13, m
60 11.2, CH3 0.84, t (7.4)
70 18.1, CH3 1.15, d (6.9)
80 19.1, CH3 0.87, d (6.6)
a Recorded in DMSO-d6.
b Recorded in CDCl3.for and the presence of a methylene proton signal (d 3.88) in 2
and the absence of methyl and hydroxy proton signals at C-9 in
1 (Table 1). The HMBC spectrum of 2 allowed us to assign the
methylene proton signal to be H2-9 on the basis of correlations
from these methylene protons to C-8, C-10, C-11 and C-13. Thus,
the structure of 2 (vanitaracin B) was elucidated (Fig. 1), and was
further conﬁrmed by 1H–1H COSY, HMQC and HMBC experiments.
The syn relationship of OH-2/H3-15 was determined from the
NOESY correlation between H-2 and H-4.
The molecular formula of C17H16O5 for compound 316 was
determined by HRESIMS. The IR spectrum showed the presence
of a hydroxy group (3369 cm1) and carbonyl groups (1727 cm1
and 1675 cm1). In the 1H NMR, a methine proton signal at d
10.07 (1H, s) indicated the presence of an aldehyde group
(Table 2). The 13C NMR spectrum revealed seventeen carbon
signals ascribable to two carbonyl, twelve aromatic, one methylene
and two methyl carbons. The 13C NMR spectrum and HMBC
correlations suggested that 3 had m-cresol and 3,5-dihydroxy-4-2b
dC, type dH (J in Hz)
37.7, CH2 3.61, dd (17.6, 3.5)
2.94, dd (17.6, 7.1)
66.8, CH 4.04, m
38.3, CH2 2.17, m
6.8) 1.60, m
.8) 27.9, CH 3.16, m
129.1, C
159.9, C
112.4, CH 6.41, s
136.3, C
42.8, CH2 3.88, s
200.8, C
85.1, C
192.6, C
121.0, C
140.8, C
22.2, CH3 1.35, d (6.8)
21.7, CH3 1.55, s
176.1, C
36.4, CH 2.69, m
5.2) 40.7, CH2 1.77, m
1.13, m
31.8, CH 1.50, m
29.4, CH2 1.32, m
1.13, m
11.1, CH3 0.88, t (7.3)
17.8, CH3 1.22, d (7.0)
19.1, CH3 0.91, d (6.7)
Table 4
Anti-HBV activity of compounds 1–5
Compounds IC50 (lM)a
1 10.5 ± 0.6
2 91.2 ± 34.5
3 51.4 ± 15.4
4 72.4 ± 70.5
5 52.1 ± 25.8
PreS1 peptideb 0.00083 ± 0.00048
a All values are the mean ± SD (n = 3 or 6).
b PreS1 peptide was used as a positive control.
Table 3
1H (600 MHz) and 13C (150 MHz) NMR spectroscopic data for compounds 4 and 5
Position 4a 5b
dC, type dH (J in Hz) dC, type dH (J in Hz)
2 164.2, C 100.3, C
3 118.6, CH 6.01, s 48.2, CH2 2.63, d (16.4)
3.18, d (16.4)
4 181.8, C 190.1, C
4a 115.4, C 114.2, C
5 143.7, C 144.5, C
5-Me 23.1, CH3 2.61, s 23.0, CH3 2.56, s
6 113.6, CH 6.58, s 113.1, CH 6.27, s
7 161.6, C 160.9, C
8 101.2, CH 6.55, s 102.2, CH 6.12, s
8a 162.9, C 161.1, C
10 49.6, CH2 3.82, s 48.8, CH2 2.76, s
20 206.8, C 212.0, C
30 36.7, CH2 2.58, q (7.3) 38.3, CH2 2.55, q (7.2)
40 7.8, CH3 1.10, t (7.3) 7.2, CH3 1.10, t (7.2)
a Recorded in CD3OD.
b Recorded in CDCl3.
Table 2
1H (600 MHz) and 13C (150 MHz) NMR spectroscopic data for compound 3 in acetone-
d6
Position 3
dC, type dH (J in Hz)
1 138.2, C
1-CHO 194.2, CH 10.07, s
2 112.3, C
3 163.6, C
4 118.0, C
4-Me 6.4, CH3 2.05, s
5 162.6, C
6 110.9, CH 6.44, s
7 46.8, CH2 4.51, s
8 203.2, C
9 128.3, C
10 136.4, C
10-Me 18.6, CH3 2.12, s
11 121.9, CH 6.83, d (7.8)
12 130.5, CH 7.16, dd (7.8, 7.8)
13 113.4, CH 6.73, d (7.8)
14 154.5, C
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Figure 3. Key HMBC correlations of compounds 3 and 4.
H. Matsunaga et al. / Bioorg. Med. Chem. Lett. 25 (2015) 4325–4328 4327methylbenzaldehyde moieties (Fig. 3). On the basis of HMBC corre-
lations from H2-7 to C-1, C-2, C-3 and a ketone carbon (C-8, d
203.2), the structure of compound 3 was determined to be
3,5-dihydroxy-2-(2-(2-hydroxy-6-methylphenyl)-2-oxoethyl)-4-
methylbenzaldehyde (Fig. 1).
The molecular formula of C14H14O4 for compound 417 was
determined by HRESIMS. The IR spectrum showed the presence
of a hydroxy group (3401 cm1) and carbonyl groups (1720 cm1
and 1650 cm1). The 13C NMR spectrum revealed all fourteen
carbon atoms, comprising two ketone carbons, eight aromatic or
oleﬁnic carbons, two sp3 methylene and two methyl carbons
(Table 3). The HMBC correlations from H3-5 to C-4a, C-5, C-6, from
H-3 to C-2 (d 164.2), C-4 (d 181.8) and C-4a, and from H-8 to C-4a,
C-6, C-7 and C-8a, indicated that 7-hydroxy-5-methyl-4H-
chromen-4-one was the partial structure (Fig. 3). The 1H–1H
COSY and HMBC correlations established the structure of a
2-butanone unit, which was connected at C-2 of the 7-hydroxy-
5-methyl-4H-chromen-4-one moiety on the basis of HMBC corre-
lations from H-10 to C-2 and C-3. Thus the structure of compound
4 was determined to be 7-hydroxy-5-methyl-2-(2-oxobutyl)-4H-
chromen-4-one (Fig. 1).
The molecular formula of C14H16O5 for compound 518 was
determined by HRESIMS. Compound 5 was found to possess an
additional oxygen atom and two additional hydrogen atoms
compared with that of 4. The 1H NMR spectrum of compound 5
was similar to that of 4, except for the presence of two aliphatic
protons at H2-3 (d 2.63 and d 3.18) in 5 and the absence of the
oleﬁnic proton in 4 (Table 3). The location of the aliphatic protons
(H2-3) was determined by HMBC correlations from H2-3 to C-10,
C-2, C-4 and C-4a. In the 13C NMR spectrum, a quaternary carbon
at d 100.3 indicated the presence of a hemiketal moiety.
Therefore, the structure of compound 5 was determined to be
2,7-dihydroxy-5-methyl-2-(2-oxobutyl)chroman-4-one (Fig. 1).Compounds 1–5 were evaluated for their anti-HBV activity
using HBV-susceptible HepG2-hNTCP-C4 cells according to a pro-
cedure described previously.19,20 The corresponding IC50 values
for all ﬁve compounds are shown in Table 4. All compounds
showed >90% cell viabilities at all concentrations tested. Of these
compounds, 1 exhibited the strongest anti-HBV activity with an
IC50 value of 10.5 lM. Intriguingly, the anti-HBV activity of com-
pound 2, which lacks methyl and hydroxy groups at C-9, was 10-
fold weaker than that of 1. These observations suggest the methyl
and hydroxy substituents at C-9 of 1 are likely to be important for
its anti-HBV activity. Weak anti-HBV activity was also displayed by
compounds 3 and 5.
In conclusion, two new tricyclic polyketides, vanitaracin A (1)
and B (2), together with novel compounds, 3,5-dihydroxy-2-(2-
(2-hydroxy-6-methylphenyl)-2-oxoethyl)-4-methylbenzaldehyde
(3), 7-hydroxy-5-methyl-2-(2-oxobutyl)-4H-chromen-4-one (4),
and 2,7-dihydroxy-5-methyl-2-(2-oxobutyl)chroman-4-one (5)
were isolated from a fungal culture broth of Talaromyces sp. The
anti-HBV activities of the isolated metabolites were evaluated,
and vanitaracin A was found to be the most potent of the tested
compounds. Dothideomycetide A that has a similar tricyclic struc-
ture to vanitaracins exhibited cytotoxicity against cancer cell lines
and antibacterial activity.21 To our knowledge, there are no reports
on anti-HBV activity of the related compounds to vanitaracins. We
believe the vanitaracin derivatives constitute a new class of anti-
HBV agents.
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